A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly

Objective  For patients with acromegaly who are suboptimally controlled on long‐acting octreotide (LAR), treatment options are to switch to pegvisomant monotherapy (PM) or add pegvisomant to LAR (P‐LAR). Our objective was to evaluate if the safety and efficacy of these regimens differ.

[1]  A. J. van der Lely,et al.  Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. , 2007, The Journal of clinical endocrinology and metabolism.

[2]  A. J. van der Lely,et al.  Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. , 2006, European journal of endocrinology.

[3]  M. D. De Martino,et al.  Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. , 2006, European journal of endocrinology.

[4]  J. Frystyk,et al.  Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  M. Vance,et al.  Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  J. Janssen,et al.  Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly , 2005, The Lancet.

[7]  M. Elmlinger,et al.  Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) , 2004, Clinical chemistry and laboratory medicine.

[8]  S. Ezzat,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY , 2004 .

[9]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  S. Ezzat,et al.  AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  D. Clemmons.  The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. , 2004, The Journal of clinical investigation.

[12]  W. Drake,et al.  Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. , 2003, European journal of endocrinology.

[13]  D. Clemmons,et al.  Growth hormone receptor antagonist improves insulin resistance in acromegaly. , 2002, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[14]  E. C. Stevens,et al.  Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. , 2002, Endocrine reviews.

[15]  X. Badia,et al.  Acromegaly Quality of Life Questionnaire (ACROQOL) a new health‐related quality of life questionnaire for patients with acromegaly: development and psychometric properties , 2002, Clinical endocrinology.

[16]  P. Freda.  Somatostatin analogs in acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.

[17]  W. Drake,et al.  A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. , 2002, The Journal of clinical endocrinology and metabolism.

[18]  J. A. Scarlett,et al.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist , 2001, The Lancet.

[19]  J. A. Scarlett,et al.  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. , 2001, The Journal of clinical endocrinology and metabolism.

[20]  H. Saito,et al.  Impaired β‐cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients , 2000, Clinical endocrinology.

[21]  M. S. Tewart,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .

[22]  J. A. Scarlett,et al.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000, The New England journal of medicine.

[23]  P. Black,et al.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.

[24]  Paul Kind,et al.  Variations in population health status: results from a United Kingdom national questionnaire survey , 1998, BMJ.

[25]  A. Harris,et al.  Effect of octreotide on glucose tolerance in acromegaly. , 1994, European journal of endocrinology.

[26]  F Pedersen,et al.  Volume of Pituitary Macroadenomas: Assessment by MRI , 1992, Journal of computer assisted tomography.